Invention Grant
US07695940B2 Gamma-1 and gamma-3 anti-human CD23 monoclonal antibodies and use thereof as therapeutics
失效
Gamma-1和γ-3抗人CD23单克隆抗体及其用作治疗剂
- Patent Title: Gamma-1 and gamma-3 anti-human CD23 monoclonal antibodies and use thereof as therapeutics
- Patent Title (中): Gamma-1和γ-3抗人CD23单克隆抗体及其用作治疗剂
-
Application No.: US11840649Application Date: 2007-08-17
-
Publication No.: US07695940B2Publication Date: 2010-04-13
- Inventor: Mitchell E. Reff , William S. Kloetzer , Takehiko Nakamura
- Applicant: Mitchell E. Reff , William S. Kloetzer , Takehiko Nakamura
- Applicant Address: US MA Cambridge
- Assignee: Biogen Idec MA Inc.
- Current Assignee: Biogen Idec MA Inc.
- Current Assignee Address: US MA Cambridge
- Agency: Sterne, Kessler, Goldstein & Fox P.L.L.C.
- Main IPC: C12P21/08
- IPC: C12P21/08 ; C12N5/12 ; C12N5/20 ; C12N5/14 ; C12N1/11 ; C12N1/19 ; C07K16/28 ; C07K16/18 ; C07H21/00
Abstract:
Monoclonal antibodies which specifically bind human CD23, the low affinity receptor for IgE (FceRII/CD23), and contain either a human gamma-1 or human gamma-3 constant domain, are disclosed. The antibodies are useful for modulating or inhibiting induced IgE expression. Accordingly, they have practical utility in the treatment or prophylaxis of disease conditions wherein inhibition of induced IgE production is therapeutically desirable, including allergic conditions, autoimmune diseases and inflammatory diseases.
Public/Granted literature
- US20090069553A1 GAMMA-1 AND GAMMA-3 ANTI-HUMAN CD23 MONOCLONAL ANTIBODIES AND USE THEREOF AS THERAPEUTICS Public/Granted day:2009-03-12
Information query
